| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453282 | Leukemia Research | 2018 | 7 Pages |
Abstract
LY2784544 demonstrated efficacy in JAK2 V617F-mutated MPNs, including in patients previously on ruxolitinib therapy, who had an ORR of 3.3%. At the 1-year visit, 44% of patients experienced a â¥50% improvement in the MPN-Symptom Assessment Form Total Symptom Score, and 26% of patients had a 50% reduction in Brief Fatigue Inventory score.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
J. Berdeja, F. Palandri, M.R. Baer, D. Quick, J.J. Kiladjian, G. Martinelli, A. Verma, O. Hamid, R. Walgren, C. Pitou, P.L. Li, A.T. Gerds,